参考文献/References:
[1] Itou M,Kawaguchi T,Taniguchi E,et al. Dipeptidyl peptidase-4：a key player in chronic liver disease[J].World J Gastroenterol, 2013,19（15）：2298-2306.
[2] Cordero OJ,Salgado FJ,Nogueira M.On the origin of serum CD26 and its altered concentration in cancer patients[J]. Cancer Immunol Immunother,2009,58（11）：1723-1747.
[3] Hatano R,Ohnuma K,Yamamoto J,et al.CD26-mediated co-stimulation in human CD8（+）T cells provokes effector func-tion via pro-inflammatory cytokine production[J]. Immunology,2013,138（2）：165-172.
[4] Vendrell J,El Bekay R,Peral B,et al. Study of the potential association of adipose tissue GLP-1 receptor with obesity and insulin resistance[J]. Endocrinology,2011,152（11）：4072-4079.
[5] Watts GF,Chan DC.Novel insights into the regulation of post-prandial lipemia by glucagon-like peptides：significance for diabetes[J]. Diabetes,2013,62（2）：336-338.
[6] Yang J,Ren J,Song J,et al. Glucagon-like peptide 1 regulates adipogenesis in 3T3-L1 preadipocytes[J].Int J Mol Med,2013,31（6）：1429-1435.
[7] Challa TD,Beaton N,Arnold M,et al. Regulation of adipocyte formation by GLP-1/GLP-1R signaling[J]. J Biol Chem,2012,
287（9）：6421-6430.
[8] Varanasi A,Patel P,Makdissi A,et al. Clinical use of liraglutide in type 2 diabetes and its effects on cardiovascular risk factors[J]. Endocr Pract,2012,18（2）：140-145.
[9] Stephan M,Radicke A,Leutloff S,et al.Dipeptidyl peptidase Ⅳ （DPP4）-deficiency attenuates diet-induced obesity in rats：possible implications for the hypothalamic neuropeptidergic system[J]. Behav Brain Res.,2011,216（2）：712-718.
[1０] Rosmaninho-Salgado J,Marquesa AP,Estrada M,et al. Dipep-tidyl-peptidase-Ⅳ by cleaving neuropeptide Y induces lipid accumulation ?酌and PPAR-?酌 expression[J].Peptides,2012,37（1）：49-54.
[11] Shimasaki T,Masaki T,Mitsutomi K,et al. The dipeptidyl peptidase-4 inhibitor des-fluoro-sitagliptin regulates brown adi-pose tissue uncoupling protein levels in mice with diet-induced obesity[J]. PLoS One,2013,8（5）：e63626.
[12] Ben-Shlomo S,Zvibel I,Shnell M,et al. Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase [J].J Hepatol,2011,54（6）：1214-1223.
[13] Miyazaki M,Kato M,Tanaka K,et al. Increased hepatic expres-sion of dipeptidyl peptidase-4 in non-alcoholic fatty liver disease and its association with insulin resistance and glucose metabolism[J].Mol Med Rep,2012,5（3）：729-733.
[14] Firneisz G,Varga T,Lengyel G,et al. Serum dipeptidyl pepti-dase-4 activity in insulin resistant patients with non-alcoholic fatty liver disease： a novel liver disease biomarker[J]. PLoS One,2010,5（8）：e12226.
[15] Turcot V,Tchernof A,Deshaies Y,et al. Comparison of the dipeptidyl peptidase-4 gene methylation levels between severely obese subjects with and without the metabolic syndrome[J]. Diabetol Metab Syndr,2013,5（1）：4.
[16] Ben-Shlomo S, Zvibel I,Rabinowich L,et al. Dipeptidyl peptidase 4-deficient rats have improved bile secretory function in high fat diet-induced steatosis[J]. Dig Dis Sci,2013,58（1）：172-178.
[17] Iwasaki T,Yoneda M,Inamori M,et al.Sitagliptin as a novel treatment agent for non-alcoholic fatty liver disease patients with type 2 diabetes mellitus [J] .Hepatogastroenterology,2011,58（112）：2103-2105.
[18] Akaslan SB,Degertekin CK,Yilmaz G,et al.Effects of sitagliptin on nonalcoholic fatty liver disease in diet-induced obese rats[J]. Metab Syndr Relat Disord,2013,11（4）：243-250.
[19] Monami M,Vitale V,Ambrosio ML,et al. Effects on lipid profile of dipeptidyl peptidase 4 inhibitors, pioglitazone,acarbose,and sulfonylureas：meta-analysis of placebo-controlled trials[J]. Adv Ther,2012,29（9）：736-746.
[2０] Kojima Y,Kaga H,Hayashi S,et al.Comparison between sitagliptin and nateglinide on postprandial lipid levels：The STANDARD study[J]. World J Diabetes,2013,4（1）：8-13.